St Jude explores migraine market for heart defect repair tool and asseses broader CRT use
This article was originally published in Clinica
St Jude Medical has joined the race to take a catheter-based heart defect repair tool to the migraine headache market. And in a separate announcement, the company said it was exploring the possibility of expanding the indications for its cardiac resynchronisation therapy (CRT) devices for treating heart failure (HF).
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.